We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
-19.64%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$240M
AUM Growth
-$51.7M
(-18%)
Cap. Flow
+$25.2M
Cap. Flow
% of AUM
10.52%
Top 10 Holdings %
Top 10 Hldgs %
50.22%
Holding
91
New
10
Increased
29
Reduced
12
Closed
11
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$6.75M |
| 2 |
Compugen
CGEN
|
+$4.71M |
| 3 |
AGTC
Applied Genetic Technologies Corporation
AGTC
|
+$4.22M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$3.78M |
| 5 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$3.7M |
Top Sells
| 1 |
ARQL
Arqule Inc
ARQL
|
+$9.94M |
| 2 |
Cytokinetics
CYTK
|
+$4.44M |
| 3 |
VYNE Therapeutics
VYNE
|
+$3.7M |
| 4 |
AtriCure
ATRC
|
+$2.84M |
| 5 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$2.65M |
Sector Composition
| 1 | Healthcare | 91.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Stereotaxis
STXS
$158M
| $41.3M | 17.24% |
13,680,554
| – | – |
|
|
BPMC
2
DELISTED
Blueprint Medicines
BPMC
| $13.3M | 5.57% |
228,089
+104,871
| +85% | +$6.75M |
|
3
Fate Therapeutics
FATE
$333M
| $10.4M | 4.36% |
470,000
| – | – |
|
|
LKFT
4
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.95B
| $9.09M | 3.79% |
46,375
-625
| -1% | -$134K |
|
5
DexCom
DXCM
$29.5B
| $8.98M | 3.75% |
133,352
-12,000
| -8% | -$747K |
|
|
6
AtriCure
ATRC
$1.78B
| $8.05M | 3.36% |
239,729
-79,000
| -25% | -$2.84M |
|
7
iShares Biotechnology ETF
IBB
$9.23B
| $7.85M | 3.28% |
72,900
+8,000
| +12% | +$921K |
|
|
ARNA
8
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $7.54M | 3.15% |
179,642
+80,700
| +82% | +$3.7M |
|
9
Neurocrine Biosciences
NBIX
$17.1B
| $6.94M | 2.9% |
80,208
+19,200
| +31% | +$1.88M |
|
10
ProQR Therapeutics
PRQR
$246M
| $6.79M | 2.83% |
1,237,400
+123,400
| +11% | +$947K |
|
11
Akebia Therapeutics
AKBA
$370M
| $6.47M | 2.7% |
853,538
+83,000
| +11% | +$646K |
|
|
LMNX
12
DELISTED
Luminex Corp
LMNX
| $5.62M | 2.34% |
204,091
| – | – |
|
|
TVRD
13
Tvardi Therapeutics
TVRD
$29.6M
| $4.9M | 2.05% |
10,306
+1,180
| +13% | +$641K |
|
|
SAGE
14
DELISTED
Sage Therapeutics
SAGE
| $4.75M | 1.98% |
165,306
+40,500
| +32% | +$2.35M |
|
|
15
Compugen
CGEN
$222M
| $4.36M | 1.82% |
+600,000
| New | +$4.71M |
|
|
AERI
16
DELISTED
Aerie Pharmaceuticals
AERI
| $3.96M | 1.65% |
293,440
+25,601
| +10% | +$486K |
|
17
Xenon Pharmaceuticals
XENE
$6.69B
| $3.93M | 1.64% |
346,535
+97,681
| +39% | +$1.39M |
|
18
Corbus Pharmaceuticals
CRBP
$167M
| $3.92M | 1.63% |
24,910
+15,000
| +151% | +$2.54M |
|
|
AGTC
19
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $3.81M | 1.59% |
1,160,878
+801,688
| +223% | +$4.22M |
|
20
Ascendis Pharma A/S
ASND
$17.4B
| $3.8M | 1.59% |
33,737
+5,637
| +20% | +$732K |
|
21
Alector
ALEC
$164M
| $3.74M | 1.56% |
155,000
+10,000
| +7% | +$255K |
|
|
ZGNX
22
DELISTED
Zogenix, Inc.
ZGNX
| $3.54M | 1.48% |
143,249
+36,500
| +34% | +$1.33M |
|
|
MRTX
23
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $3.24M | 1.35% |
+42,102
| New | +$3.78M |
|
|
BHVN
24
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $3.08M | 1.29% |
90,600
+15,900
| +21% | +$727K |
|
25
Kura Oncology
KURA
$969M
| $3.06M | 1.28% |
307,541
+134,066
| +77% | +$1.53M |
|
Similar funds
FGWP
CDMG
STCG
SCP
CAAM
AWM
HCM
CPW
DAFNA Capital Management's Q1 2020 Portfolio in Review
As of Q1 2020, DAFNA Capital Management held 91 positions worth $240M, down 18% from $291M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
DAFNA Capital Management deployed $25.2M of net new capital in Q1 2020, opening 10 new positions and adding to 29 existing holdings. Its largest new stake was Compugen: 600,000 shares worth $4.36M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier.
On the sell side, the largest reduction was AtriCure, an estimated $2.84M trimmed.
- DAFNA Capital Management's largest Q1 2020 buy was Compugen: 600,000 shares worth $4.36M.
- DAFNA Capital Management added most to Blueprint Medicines in Q1 2020, an estimated $6.75M increase.
- DAFNA Capital Management's biggest Q1 2020 reduction was AtriCure, cutting an estimated $2.84M.
- DAFNA Capital Management fully exited Arqule Inc in Q1 2020, selling an estimated $9.94M.
- DAFNA Capital Management's ten largest holdings make up 50% of its $240M portfolio in Q1 2020.
- DAFNA Capital Management opened 10 new positions and closed 11 in Q1 2020.
- DAFNA Capital Management's portfolio value fell 18% quarter-over-quarter to $240M.
Based on DAFNA Capital Management's 13F filing for Q1 2020, filed 15 May 2020.